Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0VPCQB |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | CM311-18A9-VH7/VL2 |
|||||
| Organization | SHANGHAI MIRACOGEN INC. | KEYMED BIOSCIENCES CO., LTD |
|||||
| Synonyms |
h18A9.v27
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized lgG |
|||||
| Antigen Name | Claudin-18.2 (CLDN18.2) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
| Heavy Chain Sequence |
QVQLVQSGAEVKKPGASVKVSCKPSGYTFTNYLIDWVRQAPGQGLEWMGGINPGSGDTVY
NEKFQGRVTLTADTSTSTVYMELSSLRSEDTAVYFCARRVRGNSFDSWGQGTLVTVSS Click to Show/Hide
|
|||||
| Heavy Chain CDR 1 |
GYTFTNYLID
Click to Show/Hide
|
|||||
| Heavy Chain CDR 2 |
GINPGSGDTVYNEKFQ
Click to Show/Hide
|
|||||
| Heavy Chain CDR 3 |
RVRGNSFDS
Click to Show/Hide
|
|||||
| Light Chain Sequence |
DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQKNYLAWYQQKPGQPPKLLIYWASTR
ESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNYFYPLTFGGGTKVEIK Click to Show/Hide
|
|||||
| Light Chain CDR 1 |
KSSQSLLNSGNQKNYLA
Click to Show/Hide
|
|||||
| Light Chain CDR 2 |
WASTRES
Click to Show/Hide
|
|||||
| Light Chain CDR 3 |
QONYFYPLT
Click to Show/Hide
|
|||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
CM311-18A9-VH7/VL2-ADC [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
111.1 ng/mL
|
Moderate Claudin 18.2 expression (Claudin 18.2++) | ||
| Method Description |
LT-1C8 at 5000 or 10000 cells/well, 0.7mg/ml ADCs were added and incubated for 96 hours, then CCK-8 or Presto-Blue detection reagent was added to each well, and a microplate reader was used for detection and four parameter fitting was carried out.
|
||||
| In Vitro Model | Lung lymphangioleiomyomatosis, Lymphangioleiomyomatosis | LT-1C8 cells | CVCL_8891 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
155.5 ng/mL
|
High Claudin 18.2 expression (Claudin 18.2 +++) | ||
| Method Description |
LI-M11 cells at 5000 cells/well, 0.7mg/ml ADCs were added and incubated for 96 hours, then CCK-8 or Presto-Blue detection reagent was added to each well, and a microplate reader was used for detection and four parameter fitting was carried out.
|
||||
| In Vitro Model | Lung lymphangioleiomyomatosis, Lymphangioleiomyomatosis | LI-M11 cells | CVCL_8891 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
4045 ng/mL
|
Negative Claudin 18.2 expression (Claudin 18.2-) | ||
| Method Description |
BxPC-3 at 3000 cells/well, 0.7mg/ml ADCs were added and incubated for 96 hours, then CCK-8 or Presto-Blue detection reagent was added to each well, and a microplate reader was used for detection and four parameter fitting was carried out.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cells | CVCL_0186 | ||